Biotech focused exchange traded funds (ETFs) could soon be effected by the upcoming success of Monsanto (MON), a crop biotech company. Carey Gillam of Reuters reports the company’s research and development is accelerating at a record pace and 2007 will be the biggest year yet for screening and testing genes.
Other biotech companies have been performing well and have helped push up the biotech ETFs. Amgen (AMGN) and Genentech (DNA) are top holders in the two ETFs listed below. These companies have encouraging products in the pipeline and product sales have been on the rise.
The opinions and forecasts expressed herein are solely those of Tom Lydon, and may not actually come to pass. Information on this site should not be used or construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any product.